{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:28:21Z","timestamp":1791502101161,"version":"4.3.4"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Ustekinumab, as a monoclonal antibody against interleukin (IL)-12 and IL-23, gets approved in China since 2019, therefore fewstudies report the application of ustekinumab in treating Chinese psoriasis patients in the real clinical settings until now.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>Thus, this study aimed to evaluate treatment efficacy, treatment response\u2013related factors, and safety of ustekinumab in treating Chinese psoriasis patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>Totally, 72 moderate-to-severe plaque psoriasis patients who underwent ustekinumab treatment were analyzed. Their clinical data were recorded. Furthermore, improvement of psoriasis area severity index (PASI) score more than 75% (PASI75) and improvement of PASI score more than 90% (PASI90) at week 12 and week 24 were retrieved. Besides, the adverse events were reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>There were 72.2% and 37.5% psoriasis patients who achieved PASI75 response and PASI90 response at week 12. Meanwhile, 86.7% and 46.7% psoriasis patients realized PASI75 response and PASI90 response at week 24. Besides, multivariant logistic regression analyses revealed that body mass index (BMI), disease duration, and history of tumor necrosis factor (TNF) inhibitors could independently predict reduced ustekinumab response in psoriasis patients. Additionally, the most common adverse events of ustekinumab treatment in psoriasis patients were infection (12.5%) and nasopharyngitis (9.7%), followed by headache (4.2%), cough (4.2%), abnormal hepatic function (4.2%), injection site reactions (2.8%), and eosinophilia (1.4%), which were all mild and manageable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Ustekinumab is an effective and safe immunotherapy drug for treating Chinese psoriasis patients. Furthermore, BMI, disease duration, and history of TNF inhibitors are predictors of poor ustekinumab response.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijd.ijd_232_21","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T12:21:23Z","timestamp":1716985283000},"page":"574","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Body Mass Index, Disease Duration and Tumor Necrosis Factor Inhibitor History Predict Reduced Ustekinumab Response in Chinese Psoriasis Patients"],"prefix":"10.4103","volume":"66","author":[{"given":"Xue","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zudong","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-35-20240829","first-page":"7","article-title":"Current knowledge on psoriasis and autoimmune diseases","volume":"6","author":"Ayala-Fontanez","year":"2016","journal-title":"Psoriasis (Auckl"},{"key":"R2-35-20240829","first-page":"626","article-title":"Psoriasis","volume":"87","author":"Weigle","year":"2013","journal-title":"Am Fam Physician"},{"key":"R3-35-20240829","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/1871530317666170804153751","article-title":"Current and under development treatment modalities of psoriasis: A review","volume":"17","author":"Albaghdadi","year":"2017","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"R4-35-20240829","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1590\/abd1806-4841.2019940211","article-title":"Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology","volume":"94","author":"Arnone","year":"2019","journal-title":"An Bras Dermatol"},{"key":"R5-35-20240829","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.12788\/j.sder.0071","article-title":"New and emerging therapies in psoriasis","volume":"33","author":"Leonardi","year":"2014","journal-title":"Semin Cutan Med Surg"},{"key":"R6-35-20240829","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N Engl J Med"},{"key":"R7-35-20240829","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"R8-35-20240829","first-page":"706","article-title":"Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR)","volume":"14","author":"Papp","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"R9-35-20240829","first-page":"166","article-title":"Efficacy and safety of ustekinumab in Chinese patients with moderate to severe plaque-type psoriasis: Results from a phase 3 clinical trial (LOTUS)","volume":"12","author":"Zhu","year":"2013","journal-title":"J Drugs Dermatol"},{"key":"R10-35-20240829","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis--oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"R11-35-20240829","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1111\/jdv.14114","article-title":"Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis","volume":"31","author":"Gisondi","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R12-35-20240829","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"key":"R13-35-20240829","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"R14-35-20240829","doi-asserted-by":"crossref","first-page":"e0142735","DOI":"10.1371\/journal.pone.0142735","article-title":"Interleukin-12 (IL-12)\/STAT4 axis is an important element for beta-cell dysfunction induced by inflammatory cytokines","volume":"10","author":"Weaver","year":"2015","journal-title":"PLoS One"},{"key":"R15-35-20240829","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/cphy.c170046","article-title":"Adiponectin regulation and function","volume":"8","author":"Fang","year":"2018","journal-title":"Compr Physiol"},{"key":"R16-35-20240829","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/09546634.2019.1621979","article-title":"Adiponectin levels in a large pooled plaque psoriasis study population","volume":"31","author":"Gerdes","year":"2020","journal-title":"J Dermatolog Treat"},{"key":"R17-35-20240829","doi-asserted-by":"crossref","first-page":"8061901","DOI":"10.1155\/2019\/8061901","article-title":"The oxidative stress-induced miR-200c is upregulated in psoriasis and correlates with disease severity and determinants of cardiovascular risk?","volume":"2019","author":"Magenta","year":"2019","journal-title":"Oxid Med Cell Longev"},{"key":"R18-35-20240829","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00393-017-0355-8","article-title":"Relative efficacy and safety of apremilast, secukinumab, and ustekinumab for the treatment of psoriatic arthritis","volume":"77","author":"Song","year":"2018","journal-title":"Z Rheumatol"}],"container-title":["Indian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.IJD_232_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:41:09Z","timestamp":1787769669000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijd.IJD_232_21"}},"subtitle":["A Real-World Study"],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/ijd.ijd_232_21","relation":{},"ISSN":["0019-5154"],"issn-type":[{"value":"0019-5154","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]}}}